Loading
Alligator Bioscience
Alligator Bioscience is a Swedish biotech that makes antibodies to switch on the immune system inside tumours; its CD40 agonist mitazalimab improved survival with chemotherapy in a pancreatic cancer trial.
Also called: Alligator Bioscience ABSTO:ATORX
Overview
Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer, where it produced a higher response rate and longer survival than historical chemotherapy alone, and is being prepared for phase 3. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.
Headquarters
Lund, SE
Scorecard
All companies#458of 1245 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Biotech · STO:ATORX
Stage
Public
Website
Founded
2001
Products
1Phase 2Antibody-drug conjugate
Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.
Connected
2drugs
Phase 2Antibody-drug conjugate
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
alligatorbioscience.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 193 company-less drugs to their makers and add 74 ma… · diff · file
Sourced, not expert-reviewed